Overview

Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants

Status:
Completed
Trial end date:
2021-02-13
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to investigate the safety and tolerability of BGB-DXP593 administered intravenously as a single dose in healthy participants
Phase:
Phase 1
Details
Lead Sponsor:
BeiGene